MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2021-22)
- Udyam number
- UDYAM-RJ-17-0088269
Ucardix Pharmaceuticals Private Limited
Ucardix Pharmaceuticals Private Limited - pharma in Jaipur, Rajasthan, India. Directors, charges & compliance details.
Revenue · FY 2025
₹7.56 Cr
▲ 59% YoY
Net profit · FY 2025
₹50.68 Lakh
Net margin 6.7%
EBITDA · FY 2025
₹76.69 Lakh
EBITDA margin 10.1%
Authorised capital
₹20 Lakh
Registered with MCA
Paid-up capital
₹14.5 Lakh
Issued & subscribed
Company age
5 yrs
Est. 2021
Employees · EPFO
7
Provident fund records
Directors on board
3
As per MCA filings
About Ucardix Pharmaceuticals Private Limited
Data last updated:
Ucardix Pharmaceuticals Private Limited is a private limited company based in Jaipur, Rajasthan, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 22 July 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Jaipur, under CIN U51909RJ2021PTC076007.
The company has an authorised share capital of ₹20 Lakh and a paid-up capital of ₹14.5 Lakh. It is led by directors including Pakhuri Mehta and Poonam Sharma.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Jaipur, Rajasthan.
As per the financials filed for FY 2025, the company reported a revenue of ₹7.56 Cr, a growth of 59% compared to the previous year. For the same year it recorded a net profit of ₹50.68 Lakh (net margin 6.7%) and EBITDA of ₹76.69 Lakh (EBITDA margin 10.1%). Revenue has grown at a compounded annual rate (CAGR) of 198% over three years.
The company has about 7 employees on its provident fund (EPFO) records.
Court records list 1 case involving the company, including 1 filed against it.
Ucardix Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-RJ-17-0088269). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
CIN U51909RJ2021PTC076007
Registration Number 076007
Incorporation Date 22 July 2021
ROC Jaipur
Listing Status Unlisted
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-RJ-17-0088269
Recognitions & Rankings of Ucardix Pharmaceuticals
Contact details
Ucardix Pharmaceuticals Private Limited's registered office is in Jaipur, Rajasthan.
- Registered AddressPlot No. A – 16, Bahubali Nagar Gram Manpura Devri Urf Golyawas Sanganer, Jaipur, Rajasthan, India – 302020
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Ucardix Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activities of Ucardix Pharmaceuticals are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Ucardix Pharmaceuticals Private Limited, buy the company report.
Financials of Ucardix Pharmaceuticals Private Limited
FY 2025 filings availableUcardix Pharmaceuticals Private Limited reported revenue of ₹7.56 Cr (up 59% YoY) for FY 2025.
Revenue · FY 2025
₹7.56 Cr ▲ 59%
Net profit · FY 2025
₹50.68 Lakh margin 6.7%
EBITDA · FY 2025
₹76.69 Lakh margin 10.1%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 59%
3 years · compounded
▲ 198%
EBITDA CAGR growth
1 year
▲ 142%
3 years · compounded
▲ 284%
Revenue has grown at a compounded annual rate (CAGR) of 198% over three years, including 59% growth in the latest year. EBITDA rose 142% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ₹76.69 Lakh | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | ₹50.68 Lakh | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 10.1% | |||
| Net Profit Margin | 6.7% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Ucardix Pharmaceuticals Private Limited, buy the company report.
Board of directors of Ucardix Pharmaceuticals Private Limited
Ucardix Pharmaceuticals has 3 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pakhuri Mehta | Director | 22 Jul 2021 | 5 Years 3 Months | Current |
| Poonam Sharma | Director | 22 Jul 2021 | 5 Years 3 Months | Current |
| Maya Sharma | Director | 22 Jul 2021 | 5 Years 3 Months | Current |
Legal cases
Ucardix Pharmaceuticals Private Limited has 1 court case on record: 1 filed against it. All case is disposed.
Total cases
1
Filed against the company
1
Disposed
1
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 1 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Court case (LPETN) | Filed against the company by Cachet Pharmaceuticals Pvt Ltd | Disposed |
To see the full case history of Ucardix Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Ucardix Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Ucardix Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Ucardix Pharmaceuticals Private Limited has 3 board changes on record since 2021: 3 appointments. The latest: Maya Sharma was appointed as Director on 22 Jul 2021.
AGM
Ucardix Pharmaceuticals Private Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Filing
Ucardix Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Jaipur.
Appointed
Maya Sharma was appointed as Director.
Appointed
Pakhuri Mehta was appointed as Director.
Appointed
Poonam Sharma was appointed as Director.
Incorporation
22 Jul 2021
Ucardix Pharmaceuticals Private Limited was registered on 22 Jul 2021 with Roc Jaipur & aged 5 years 3 months as per MCA records.
Frequently asked questions
Ucardix Pharmaceuticals is an active private limited company based in Jaipur, Rajasthan, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 22 July 2021 (5+ years old) and is registered under CIN U51909RJ2021PTC076007.
Ucardix Pharmaceuticals has 3 current directors:
- Pakhuri Mehta - Director
- Poonam Sharma - Director
- Maya Sharma - Director
The latest financial statements of Ucardix Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from FY 2022 are in the company report.
The CIN (Corporate Identification Number) of Ucardix Pharmaceuticals is U51909RJ2021PTC076007. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ucardix Pharmaceuticals has 1 court case on record: 1 filed against it.
Ucardix Pharmaceuticals was incorporated on 22 July 2021, making it 5+ years old. It is registered with the Registrar of Companies, Jaipur.
Maya Sharma was appointed as Director on 22 Jul 2021. Pakhuri Mehta was appointed as Director on 22 Jul 2021. Poonam Sharma was appointed as Director on 22 Jul 2021.
Yes, Ucardix Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-RJ-17-0088269).
The registered office of Ucardix Pharmaceuticals is at Plot No. A – 16, Bahubali Nagar Gram Manpura Devri Urf Golyawas Sanganer, Jaipur, Rajasthan, India – 302020.
Ucardix Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.